Know Cancer

or
forgot password

Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients


N/A
18 Years
N/A
Not Enrolling
Both
Leukemia, Hodgkin Disease, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Multiple Myeloma

Thank you

Trial Information

Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients


Inclusion Criteria:



- Scheduled to receive nonmyeloablative conditioning which includes fludarabine

- Scheduled to receive a haploidentical graft

- Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate
mofetil (MMF) or enteric-coated mycophenolic acid

- Age >18 years at the time of enrollment

Exclusion Criteria:

- Diagnosed with an immunodeficiency disorder, including HIV

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Donor T-cell chimerism

Outcome Time Frame:

Day 28 post-transplant

Safety Issue:

No

Principal Investigator

Jeannine McCune, PharmD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center

Authority:

United States: Institutional Review Board

Study ID:

FHCRC-2373.00

NCT ID:

NCT01141959

Start Date:

May 2010

Completion Date:

December 2011

Related Keywords:

  • Leukemia
  • Hodgkin Disease
  • Non-Hodgkin Lymphoma
  • Myelodysplastic Syndrome
  • Multiple Myeloma
  • hematopoietic stem cell transplantation
  • cyclophosphamide
  • fludarabine
  • mycophenolate mofetil
  • mycophenolic acid
  • biomarkers
  • Hodgkin Disease
  • Leukemia
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location
Fred Hutchinson Cancer Research Center Seattle, Washington  98109